Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (532)	4/25/1999 12:42:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 4474

I am your humble servant... mayo.edu ARIAD patent (U.S. Patent No. 5,871,753, issued on February 16, 1999) cover Dimerizer Drugs(TM) that bind to certain immunophilin or cyclophilin proteins. Such drugs are useful in regulating biological activity of genetically engineered cells. Of course when I find stuff on the net, I really don't know whether it is a little nugget, or clue, or whether I find fools gold... Maybe Miljenko will stop by and give a primer on the immunophilin pathway--shed some light on what the aria patent might mean in terms of the research going on and any potential for where Ariad, Vertex andn others are headed with this work...